Importancia de la construcción de política pública para el control del

comparison of L-dopa, 1-deprenyl and dopaminoagonists. Study design and short term results. The Italian Parkinson Study Group. Ital J Neurol Sci 1992;13:735- 739. (Not in English)

Bayulkem K, ErisirK, Tuncel A, Bayulkem B. A study on the effect and tolerance of lisuride on Parkinson’s disease. Adv Neurol 1996;69:519-530. (Book chapter) Capria A, Attanasio A, Quatrana M, et al. Cardiovascular effects of lisuride continu-

ous intravenous infusion in fluctuating Parkinson’s disease. Clin Neuropharmacol 1989;12:331-338. (Non-parkinsonian endpoint)

Caraceni T. A case for early levodopa treatment of Parkinson’s disease. Clin Neuropharmacol 1994;18:S38-S42. (Insufficient description of methods) Casacchia M, Meco G, Castellana F, Bedini L, Cusimano G, Agnoli A. Therapeutic

use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson’s disease. Pharmacol Res Commun 1983;15:329-334. (Study on rolipram) Chouza C, Caamano JL, de Medina O, Aljanati R, Scaramelli A, Romero S. A com-

bined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson’s disease. J Neural Transm Suppl 1988;27:61-70. (< 20 patients)

Critchley PH, Grandas Perez F, Quinn NP, Parkes JD, Marsden CD. Continuous subcutaneous lisuride infusions in Parkinson’s disease. J Neural Transm 1988;27:55-60. (< 20 patients).

De Yebenes JG, Fahn S, Lovelle S, et al. Continuous intracerebroventricular infu- sion of dopamine and dopamine agonists through a totally implanted drug deliv- ery system in animal models of Parkinson’s disease. Mov Disord 1987;2:143- 158. (Animal data)

Destée A, Defebvre L, Fondarai J, Patay M. Early combination of lisuride and levodopa in the treatment of Parkinson’s disease. Comparison with levodopa alone during a double-blind then open trial: a 3-year follow-up. J Neurol 1996;243:S79. (Abstract)

Djaldetti R, Melamed E. Management of response fluctuations: practical guide- lines. Neurology 1998;51:S36-40. (Review)

Fernandez Pardal M, Micheli F, Gatto M, Perez y Gonzalez N. Treatment of Parkinson’s disease with subcutaneous lisuride infusions. J Neural Transm Suppl 1988;27:75-84. (< 20 patients)

Foster NL, Newman RP, Le Witt WPA, Gillespie MM, Chase TN. Treatment of resting tremor by beta-adrenergic blockade. Am Heart J 1984;108:1173-1177. (Study on nadolol)

Gershanik OS, Scipioni O, Garcia S. Lisuride infusion pump in Parkinson’s dis- ease. A report of two cases. J Neural Trans Suppl 1988;27:85-90. (< 20 patients) Giovannini P, Scigliano G, Grassi MP, Carella F, Parti E, Caraceni T. Bromocriptine- lisuride cross tolerance. Ital J Neurol Sci 1983;4:129-130. (Non-English litera- ture)

Giovannini P, Scigliano G, Piccolo I, Soliveri P, Suchy I, Caraceni T. Lisuride in de novo parkinsonian patients: a four-year follow-up. Acta Neurol Scand 1988;77:322-327. (Level III; less than 20 patients per treatment group) Giovannini P, Scigliano G, Piccolo I, Soliveri P, Suchy I, Caraceni T. Lisuride in

Parkinson’s disease. 4-year follow-up. Clin Neuropharmacol 1988;11:201-211. (Less than 20 patients per treatment group)

Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. International Pramipexole- Bromocriptine Study Group. Neurology 1997;49:1060-1065. (Study on pramipexole and bromocriptine)

Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson’s disease. A clini- cal and neuropharmacological study. Brain 1984;107:487-506. (Level III) Hayashi R, Tako K, Makishita H, Koyama J, Yanagisawa N. Efficacy of a low-dose

subcutaneous lisuride infusion in Parkinson’s disease. Intern Med 1998;37:444- 448. (< 20 patients)

Krause W, Nieuweboer B, Ruggieri S, Stocchi F, Suchy I. Pharmacokinetics of lisuride after subcutaneous infusion. J Neural Transm Suppl 1988;27:71-74. (< 20 patients)

Lees AJ, Stern GM. Pergolide and lisuride for levodopa-induced oscillations. Lan- cet 1981;2(8246):577. (Level III)

Lestingi L, Bonifati V, Stocchi F, Antonozzi I, Meco G. TRH test and the continuous dopaminergic stimulation in complicated Parkinson’s disease. Eur Neurol 1992;32:65-69. (Non-parkinsonian endpoints; < 20 patients)

LeWitt PA, Burns RS, Calne DB. et al. Lisuride treatment in Parkinson’s disease: clinical and pharmacokinetic studies. Adv Neurol 1983;37:131-140. (Book chap- ter)

LeWitt PA, Ward CD, Larsen TA, et al. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology 1983;33:1009-1014. (Study on pergolide and bromocriptine)

Lieberman A, Goldstein M, Neophytides A, et al. Lisuride in Parkinson disease: efficacy of lisuride compared to levodopa. Neurology 1981;31:961-965. (Level III; less than 20 patients per treatment group)

Lieberman AN, Goldstein M, Leibowitz M, et al. Lisuride combined with levodopa in advanced Parkinson disease. Neurology 1981;31:1466-1469. (Level III) Ludwig CL, Weinberger DR, Bruno G, et al. Buspirone, Parkinson’s disease, and

the locus ceruleus. Clin Neuropharmacol 1986;9:373-378. (Study on buspirone) Luquin MR, Obeso JA, Vaamonde J, Martinez Lage JM. Orally administered lisuride

in the treatment of complex fluctuations of motion in Parkinson disease. Neurologia 1989;4:229-232. (Non-English literature; Spanish)

Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson’s disease: clinical and pharmacological classification. Mov Disord 1992;7:117-124. (Review)

Marti Masso JF, Urtasun M. Citicoline in the treatment of Parkinson’s disease. Clin Ther 1991;13:239-242. (Study on citicoline)

Martignoni E, Horowski R, Liuzzi A, et al. Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: a double-blind study ver- sus placebo. Clin Neuropharmacol 1996;19:72-80. (Study on terguride) Martignoni E, Pacchetti C, Aufdembrinke B, et al. Terguride in stable Parkinson’s

disease. Funct Neurol 1995;10:143-146. (Study on terguride)

Meneghetti G, Bracco F, Giometto B, Ferla S, Schergna E. Therapeutic effect of lisuride in advanced Parkinson’s disease. Eur Neurol 1986;25:74-80. (Level III; < 20 patients per treatment group)

Micieli G, Martignoni E, Bono G, et al. A study of the cardiopressor effects of lisuride in the treatment of parkinsonism and pathological aging brain. Clin Neuropharmacol 1989;12:404-415. (Non-parkinsonian endpoint)

Micieli G, Martignoni E, Cavallini A, et al. Lisuride and bromocriptine in L-dopa stable-responder parkinsonian patients: a comparative, double-blind evaluation of cardiopressor and neurochemical effects. Funct Neurol 1996;11:317-325. (Non- parkinsonian endpoints)

Nappi G, Martignoni E, Horowski R, et al. Lisuride plus selegiline in the treatment of early Parkinon’s disease. Acta Neurol Scand 1991;83:407-410. (Study on selegiline)

Obeso JA, Luquin MR, Martinez-Lage JM. Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson’s disease. Lancet 1986;1(8479):467- 470. (< 20 patients)

Obseso JA, Luquin MR, Vaamonde J, Grandas F, Martinez Lage JM. Continuous dopaminergic stimulation in Parkinson’s disease. Can J Neurol Sci 1987;14:488- 492. (Review)

Pacchetti C, Martignoni E, Bruggi P, et al. Terguride in fluctuating parkinsonian patients: a double-blind study versus placebo. Mov Disord 1993;8:463-465. (Study on terguride)

Pochlau D, Baier JE, Kovaes S, et al. Is dopaminergic therapy immunologically rejuvinating? Increased interferon-gamma production with the dopaminergic agent lisuride. Fortschr Med 1994;112:174-176. (Non-English literature)

Poungvarin N, Prayoonwiwat N, Devahasatin V, Viriyavejakul A. An open label trial of pergolide in Thai patients in Parkinson’s disease. J Med Assoc Thai 1996;79:205-209. (Study on pergolide)

Ruggieri S, Stocchi F, Carta A, et al. One year treatment with lisuride delivery pump in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:173- 183. (< 20 patients)

Stibe C, Lees A, Stern G. Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations. Lancet 1987;1(8537):871. (< 20 patients)

Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkin- sonian on-off oscillations. Lancet 1988;1:403-406. (Study on apomorphine) Stocchi F, Nordera G, Marsden CD. Strategies for treating patients with advanced

Parkinson’s disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol 1997;20:95-115. (Review)

Stocchi F, Patsalos PN, Berardelli A, et al. Clinical implications of sustained dopam- inergic stimulation. Clin Neuropharmacol 1994;17:S7-13. (< 20 patients) Stocchi F, Ruggieri S, Antonini A, et al. Subcutaneous lisuride infusion in Parkinson’s

disease: clinical results using different modes of administration. J Neural Transm Suppl 1988;27:27-33. (< 20 patients)

Todes CJ. At the receiving end of the lisuride pump. Lancet 1986;2(8497):36-37. (< 20 patients)

Vaamonde J, Luquin MR, Obeso JA. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson’s dis- ease. Mov Disord 1990;5:260-262. (Study on apomorphine)

Vermersch P, Fondarai J, Petit H. [Randomized study during a year of early combi- nation of L-dopa/lisuride in Parkinson disease]. Therapie 1991;46:481-486. (Non- English literature; French)

Wachtel H, Rettig KJ, Loschmann PA. Effect of chronic subcutaneous minipump infusion of lisuride upon locomotor activity of rats. J Neural Trans Suppl 1988;27:177-183. (Animal study).

S79